Autoantibodies against signal recognition particle (SRP) and 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) play a crucial role in the pathogenesis of immune-mediated necrotizing myopathies (IMNMs).^[@R1],[@R2]^ Levels of autoantibody titres are directly linked to disease activity, and treatment response can be monitored by measuring the levels of autoantibodies in both anti-SRP-- and anti-HMGCR--associated necrotizing myopathies.^[@R3]^ Antigens to these antibodies persist over a long time in the human body and stimulate the immune system in a specific way. In contrast to sporadic inclusion body myositis (sIBM), which is characterized by the presence of cytotoxic granzyme B^+^ and/or perforin^+^ T cells,^[@R4]^ IMNM is a paucilymphocytic disease. We have recently highlighted the presence of T cells in all examined IMNM biopsies; however, we showed that in IMNM, T cells lack robust cytotoxicity.^[@R1]^ As opposed to IMNM, the specificity of an autoantibody (cN1A) in sIBM is less clear.^[@R5][@R6][@R7]^ Hence, persistence of antigens in IMNM may affect the phenotype of T cells in this disease. Indeed, T cells, exposed to persistent antigen and inflammatory molecules, may functionally deteriorate, a process called T-cell exhaustion.^[@R8]^ Exhausted T cells are subject to complex negative regulation involving signaling through multiple receptors that inhibit functional and proliferative responses, which in turn result in ineffective control of the inflammation.^[@R9]^ The CD28 family member programmed cell death protein 1 (PD1) is the most highly expressed inhibitory receptor on CD8^+^ T cells during chronic inflammation, and this receptor has a major role in regulating T-cell exhaustion. The role of PD1 expression in healthy adult humans to distinguish between effector T cells and exhausted T cells as well as the interpretation of increased expression levels of PD1 in infection as a single marker of exhaustion, however, has been much debated.^[@R10],[@R11]^ Interestingly, PD1 has been shown to be upregulated early after T-cell activation and is not exclusively associated with states of T-cell dysfunction.^[@R12]^ Importantly, blockade of the PD1 signaling pathway can restore appropriate antigen-specific T-cell responses in chronic infection and in the tumor environment.^[@R8]^ Immune checkpoint inhibitors (ICIs) successfully lead to tumor immune rejection in certain cancers by reactivating tumor response in exhausted T cells.^[@R13]^ However, therapy with these agents causes increased autoimmune responses with development of adverse effects including myositis and myocarditis.^[@R14]^ Exhaustion, anergy, and senescence are common concepts to describe dysfunctional states of T cells associated with increased expression of immune checkpoints, which may harbor overlapping, yet distinctive features, one of which is expression of CD57---low in exhaustion, but high in senescence.^[@R9],[@R15],[@R16]^ Senescent T cells enter a terminal differentiation state owing to excessive cell replication, a process that is associated with irreversible cell cycle arrest and telomere shortening. CD57^+^ T cells have been studied in sIBM.^[@R17]^

In this study, we hypothesized that persistent antigen presentation in immune-mediated myopathies leads to dysfunctional states of invading T cells. This finding would provide further evidence for a direct recognition of muscular antigens by invading T cells, and a role for T cells in the pathogenesis of these diseases. In addition, we analyzed molecules driving T-cell exhaustion and senescence in skeletal muscle biopsies from IMNM with anti-SRP or anti-HMGCR antibodies and sIBM as well as ICI-associated immune toxicity-related myositis induced by immune checkpoint inhibitors (irMyositis).

Methods {#s1}
=======

Patients {#s1-1}
--------

Clinical data of all patients enrolled in this study are listed in the [table](#T1){ref-type="table"}. We included patients with clinical, serologic, and morphologic signs and symptoms consistent with IMNM^[@R18]^ and sIBM according to present criteria,^[@R19]^ as well as patients treated with ICIs suffering from ICI-induced myositis.

###### 

Characteristics of all patients included in the study

![](NEURIMMINFL2018018507t1)

Standard protocol approvals, registrations, and patient consents {#s1-2}
----------------------------------------------------------------

Informed consent was obtained from all patients at each institution involved. The Charité Ethics Committee (EA2/163/17), the French Ministry of Research, as well as the Research Ethics Committee of the Pitié-Salpêtrière Hospital (Paris, France) (AC 2008-87) granted ethical approval.

Skeletal muscle specimens {#s1-3}
-------------------------

We analyzed skeletal muscle biopsies from 12 patients diagnosed with IMNM according to the clinico-sero-morphologic European Neuromuscular Centre criteria.^[@R18]^ Also, skeletal muscle biopsies from 7 patients with sIBM were included (clinically and morphologically definite sIBM)^[@R19]^ and 9 patients with myositis as an adverse event after ICI treatment according to recent data.^[@R20]^ In addition, we investigated control skeletal muscle biopsies (n = 8) from patients with nonspecific myalgia, in whom muscle weakness and morphologic abnormalities in skeletal muscle biopsies were absent; creatine kinase levels were normal; no signs of systemic inflammation and no myositis-specific antibodies (MSAs) or myositis-associated antibodies had been detected. All skeletal muscle specimens had been cryopreserved at −80°C prior to analysis.

Morphologic analysis {#s1-4}
--------------------

All stains were performed on 7 μm cryomicrotome sections, according to standard procedures. Immunohistochemical and double immunofluorescence stains were obtained as described previously.^[@R21]^ The following antibodies were used for staining procedures: (primary antibody, dilution, company/clone): mouse anti-human CD3, 1:50, Dako/UCHT1; mouse anti-human CD68, 1:100 Dako/EBM1; MHCI, 1:1.000, Dako/w6/32; PD1, 1:100, Abcam/NAT105; PDL1, 1:100, Cell signalling/E1L3N; PDL2, 1:100, Abcam/Ty25.

RNA extraction and PCR {#s1-5}
----------------------

Total RNA extraction from muscle specimens and quantitative reverse transcription PCR were performed as described previously.^[@R21]^

cDNA was synthesized using the High-Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA). For quantitative PCR (qPCR) reactions, 2 ng of cDNA were used, and for analysis, the 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA) was used, running conditions: 95°C 0:20, 95°C 0:01, 60°C 0:20, 45 cycles (values above 40 cycles were defined as not expressed). All genes were run as triplicates, and each run contained the reference gene (PGK1) as internal control, to normalize the expression of the target genes. The qPCR assay identification numbers, TaqMan Gene Exp Assay from Life Technologies/ThermoFisher are listed as follows:

*CD28*, Hs01007422_m1; *CD39*, Hs00969556_m1; *CD80*, Hs01045161_m1; *CD244*, Hs00175569_m1; *EOMES*, Hs00172872_m1; *IL7R*, Hs00902334_m1; *KLRG1*, Hs00195153_m1; *LAG3*, Hs00958444_g1; *PD1*, Hs01550088_m1; *PDL1*, Hs00204257_m1; *PDL2*, Hs00228839_m1; *PGK1*, Hs99999906_m1 *TBX21*, Hs00894392_m1; *TIM3*, Hs00958618_m1; *VISTA*, Hs00735289_m1.

The ΔCT of healthy controls was subtracted from the ΔCT of patients with IMNM to determine the differences (ΔΔCT) and fold change (2\^−ΔΔCT) of gene expression. Gene expression was illustrated by the log10 of fold change values compared to the healthy controls.

Statistical analysis {#s1-6}
--------------------

Kruskal-Wallis one-way analysis of variance followed by Bonferroni-Dunn correction of the post hoc tests was used to analyze quantitative differences of messanger ribonuclein acid (mRNA) transcripts. Data are presented as mean ± standard error of the mean. The level of significance was set at *p* \< 0.05. GraphPad Prism 5.02 software (GraphPad Software, Inc, La Jolla, CA) was used for statistical analysis.

Data availability statement {#s1-7}
---------------------------

The authors of this manuscript state that they have carefully documented data, methods, and materials used to conduct the research in the article. Data not provided in the article because of space limitations can be made available at the request of other investigators for purposes of replicating procedures and results. To our knowledge, there are no legal or ethical reasons or any embargoes on datasets, which may restrict these data availability policy.

Results {#s2}
=======

Clinical data {#s2-1}
-------------

For the analysis of exhaustion and senescence markers, we included 12 patients with IMNM (7 male, mean age 47 \[18--80\]), 7 with sIBM (6 male, mean age 70 \[64--75\], 9 with irMyositis (7 male, mean age 71 \[56--87\]), and 8 healthy controls (6 male, mean age 30 \[2--49\]) ([table](#T1){ref-type="table"}).

Of all patients with IMNM, 59% (7 patients) harbored anti-SRP autoantibodies, 41% (5 patients) had anti-HMGCR autoantibodies, and for the patients with sIBM, the autoantibody status for NT5C1A was unknown and not obtainable retrospectively. One patient with ICI-related myositis had anti-Sjögren syndrome--related antigen A autoantibodies. No other MSAs were found in this cohort.

Expression and localization of PD1 and its cognate ligands PD-L1 and PD-L2 in IMNM, sIBM, and irMyositis {#s2-2}
--------------------------------------------------------------------------------------------------------

We were not able to detect any significant difference between biopsies from SRP- and HMGCR-positive patients with IMNM either by qPCR analyses or by immunohistochemical stains ([figure 1](#F1){ref-type="fig"}). We will, therefore, report all results for both SRP- and HMGCR-positive IMNM as one IMNM phenotype.

![Log10-fold changes of markers of T-cell exhaustion and senescence in samples from patients with IMNM\
We did not observe statistically significant differences between patients with anti-SRP and anti-HMGCR autoantibodies. Statistical analysis was performed using Kruskal-Wallis one-way analysis of variance with Dunn multiple comparison test. HMGCR = hydroxy-3-methylglutaryl-coenzyme A reductase; SRP = signal recognition particle.](NEURIMMINFL2018018507f1){#F1}

In skeletal muscle biopsies of patients with IMNM, CD3^+^ T cells were mostly PD1 positive ([figure 2, A and D](#F2){ref-type="fig"}). Ligand of programmed cell death protein 1 (PD-L1) was only expressed on macrophages in the endomysium, within myophagocytosis, and not on the sarcolemma of myofibers ([figure 2B](#F2){ref-type="fig"}). PD-L1^+^ macrophages did not closely interact with PD1^+^ T cells. The sarcolemma of myofibers was weakly PD-L2^+^, the expression of which is colocalized with major histocompatibility complex (MHC) class I ([figure 2, C and G](#F2){ref-type="fig"}). PD1^+^ T cells are localized adjacent to PD-L2^+^ sarcolemmal structures---thus may form an immunologic synapse ([figure 2F](#F2){ref-type="fig"}). PD-L2 was also expressed on many CD68^+^ macrophages ([figure 2E](#F2){ref-type="fig"}).

![Immunohistochemical stains of skeletal muscle biopsies from patients with IMNM, sIBM, or irMyositis\
In IMNM biopsies, PD1+ cells are diffusely distributed in the endomysium (A) and most of them correspond to CD3^+^ T cells (D). Macrophages in myophagocytosis and endomysial macrophages are PD-L1+ (B) but the sarcolemma of myofibers is not (B). CD68 ^+^ macrophages coexpress PD-L2 (E), they colocalize with MHC class I+ sarcolemmal membranes (G), and PD1+ lymphocytes interact with PD-L2+ sarcolemmal structures (F) (A and C, original magnification ×200; B, original magnification ×400; D-F, original magnification ×600). In sIBM biopsies, PD1+ cells are CD3^+^, and they are detectable in the endomysium surrounding myofibers (H, K). PD-L1 is faintly detectable in macrophages within myophagocytosis but not on the sarcolemma and not on endomysial or perimysial macrophages (I). The sarcolemma of myofibers and macrophages are PD-L2+ and colocalize with sarcolemmal MHC class I (J, N). CD68 ^+^ macrophages coexpress PD-L2 (L), and PD1+ lymphocytes only occasionally interact with PD-L2+ sarcolemmal structures (M) (H-J, original magnification ×200; K-N, original magnification ×600). In irMyositis, PD1+ cells are detectable in the endomysium and they are CD3^+^ with variable intensity (O, R). PD-L1 is positive on macrophages but not all CD68 ^+^ macrophages express PD-L1 (P). The sarcolemma of myofibers is moderately PD-L2 positive (Q) and faintly coexpresses MHC class I (U). CD68 ^+^ macrophages interact with PD-L2+ sarcolemmal structures (S). Single PD1+ T cells interact with PD-L2 sarcolemmal structures (T) (O-Q, original magnification ×200; R-U original magnification ×600). IMNM = immune-mediated necrotizing myopathy; irMyositis = myositis induced by immune checkpoint inhibitors; sIBM = sporadic inclusion body myositis.](NEURIMMINFL2018018507f2){#F2}

In skeletal muscle biopsies of patients with sIBM, numerous CD3^+^ T cells were PD1 positive ([figure 2, H and K](#F2){ref-type="fig"}). PD-L1 was weakly expressed on single macrophages in myophagocytosis or in the endomysium, and not on the sarcolemma of myofibers ([figure 2I](#F2){ref-type="fig"}). PD-L1^+^ macrophages did not show close interaction with PD1^+^ T cells. The sarcolemma of myofibers was PD-L2^+^, the expression of which is intensely colocalized with MHC class I ([figure 2, J and N](#F2){ref-type="fig"}). PD1^+^ T cells only occasionally interacted with PD-L2^+^ sarcolemmal structures ([figure 2M](#F2){ref-type="fig"}). PD-L2 was also expressed on many CD68^+^ macrophages and was co-localized with the sarcolemma of MHC class I^+^ myofibers ([figure 2, L and N](#F2){ref-type="fig"}).

In skeletal muscle biopsies of patients with irMyositis, PD1^+^ T cells were diffusely distributed and frequently clustered close to myofiber necrosis ([figure 2O](#F2){ref-type="fig"}). PD-L1 was strongly positive on many endomysial CD68^+^ macrophages and in myophagocytic lesions but not on the sarcolemma of myofibers ([figure 2, P,R,T](#F2){ref-type="fig"}). PD1^+^ T cells only occasionally interacted with PD-L2^+^ sarcolemmal structures ([figure 2T](#F2){ref-type="fig"}). PD-L2 was strongly positive on the sarcolemma of myofibers and was colocalized with MHC class I ([figure 2, Q, S, U](#F2){ref-type="fig"}).

Molecular expression of exhaustion and senescence markers in IMNM, sIBM, and irMyositis {#s2-3}
---------------------------------------------------------------------------------------

Consistent with our findings from immunohistochemical stains, expression levels of *PD1 (PDCD1)*, *PDL1 (CD274)*, and *PDL2 (PDCD1LG2)* in IMNM samples were overall increased by qPCR analyses. Expression levels showed a large variance among individual patients and differences to healthy controls were nonsignificant in statistical analyses. Patients with high expression of *PD1*, however, also showed high expression levels of other markers of T-cell exhaustion and vice versa ([figure 3A](#F3){ref-type="fig"}). The T-cell exhaustion marker *TIM3* was significantly elevated in IMNM samples (compared to healthy controls). We did not find increased expression levels of markers of T-cell senescence in our IMNM samples ([figure 3, B and C](#F3){ref-type="fig"}). Conversely, we observed clear signs of both T-cell senescence and T-cell exhaustion in sIBM samples. mRNA levels for characteristic T-cell exhaustion markers *PD1*, *EOMES*, *TBX21*, *LAG3*, *CD244*,^[@R8]^ and *KLRG1* were significantly increased ([figure 3, B and C](#F3){ref-type="fig"}). The PD1 ligand *PDL2* was also significantly increased ([figure 3A](#F3){ref-type="fig"}). Despite significant elevation of *KLRG1* as a marker of T-cell senescence, *CD28* and *CD80* were also significantly elevated in the sIBM samples. *IL7R*, which has been shown to be downregulated in T-cell exhaustion, was significantly upregulated ([figure 3C](#F3){ref-type="fig"}). In irMyositis, we observed 2 distinct subsets of expression pattern. In samples of 2 patients with irMyositis, we found clear signs of T-cell senescence, but not of T-cell exhaustion. In these cases, surface expression of CD57 on immunohistochemical stains was high while gene expression of *PD1* and *CD28* were suppressed. These 2 patients had a severe clinical phenotype, leading to death of an associated myocarditis in one case. In all other cases, CD57 surface expression was undetectable, while *TIM3* and *LAG3* as well as *PDL1* and *PDL2* expression were significantly increased ([figure 3, A--C](#F3){ref-type="fig"}).

![Markers of T-cell exhaustion and senescence in patient skeletal muscle samples\
mRNA levels of genes related to T-cell exhaustion (A and B) and T-cell senescence (C) from IMNM (n = 12), sIBM (n = 7), and irMyositis (n = 9) samples. Statistical analysis was performed using Kruskal-Wallis one-way analysis of variance with Dunn multiple comparison test. \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001---difference between displayed groups in log fold changes. \#*p* \< 0.05; \#\#*p* \< 0.01; \#\#\#*p* \< 0.001---differences between dCT of patient groups and normal control. IMNM = immune-mediated necrotizing myopathy; irMyositis = myositis induced by immune checkpoint inhibitors; sIBM = sporadic inclusion body myositis.](NEURIMMINFL2018018507f3){#F3}

Expression of inflammatory markers in sIBM and IMNM {#s2-4}
---------------------------------------------------

To further characterize the nature and the effect of the observed T-cell subsets in sIBM and IMNM, we investigated markers of inflammation and T-cell activation in muscle biopsies of patients with IMNM and sIBM. In sIBM samples, we found strong upregulation of gene expression of gamma interferon (*IFNγ*), *IL6*, and *IL12*. These markers were also increased in IMNM samples regardless of the antibody subtype (HMGCR or SRP) but to a lower degree ([figure 4](#F4){ref-type="fig"}).

![Markers of inflammation in IMNM (n = 42) and sIBM (n = 7) skeletal muscle samples\
Markers for interstitial inflammation were upregulated in samples of IMNM and sIBM. All changes were significant at *p* \< 0.01 compared to control samples (n = 8). TNFα and IFNγ levels differed significantly between IMNM and sIBM samples. Statistical analysis was performed using Kruskal-Wallis one-way analysis of variance with Dunn multiple comparison test. \**p* \< 0.05---difference between displayed groups in log fold changes. IMNM = immune-mediated necrotizing myopathy; sIBM = sporadic inclusion body myositis.](NEURIMMINFL2018018507f4){#F4}

Discussion {#s3}
==========

In this study, we provide systematic evidence of the presence of dysfunctional T cells and activation of the PD1 pathway in IMNM, inclusion body myositis, and immune toxicity-related myopathy. This finding has implications for the understanding of the role of T cells in the pathogenesis of these diseases. States of T-cell exhaustion and senescence have been studied extensively in chronic viral infections and cancer, and are associated with prolonged antigen exposure and subsequent adverse effects on T-cell function.^[@R9],[@R22],[@R23]^ The role of T-cell exhaustion and T-cell senescence in autoimmune disease has gathered increased interest in recent years,^[@R24],[@R25]^ and co-inhibitory receptors have been shown to play a role in regulating severity of autoimmune disease.^[@R26]^ Despite a heterogeneously used nomenclature, T-cell exhaustion and senescence are actively regulated and, at least in part, reversible T-cell states associated with defective T-cell function.^[@R8]^

In this study, we demonstrate that T-cell exhaustion and senescence can be detected in sIBM and IMNM. We were also able to demonstrate that in irMyositis, T cells with an exhausted phenotype invade the skeletal muscle tissue, and that myofibers upregulate ligands of the inhibitory coreceptor PD1. Upregulation of PD-L1 and PD-L2 has been demonstrated in several autoimmune diseases,^[@R27][@R28][@R29]^ and PD-L1/PD-1 and PD-L2/PD-1 interaction has been reported to control the severity of autoimmune disease.^[@R29]^ Furthermore, PD-L1 has been reported to be expressed on muscle fibers in sIBM, polymyositis, and dermatomyositis in vivo and to inhibit T-cell activation in vitro.^[@R30]^ Using double immunohistochemistry/fluorescence, we were able to detect expression of PD1 ligands PD-L1 on macrophages and PD-L2 on myofibers in sIBM, IMNM, and irMyositis. PD-L2 staining on myofibers was partially overlapping PD1 staining on CD3^+^ lymphocytes, implicating the formation of so called "immunologic synapses" and a potential role of PD-L2/PD1 interaction in modulating T-cell activation.^[@R31]^ These findings were also reflected by significantly increased *PDL2* mRNA levels in sIBM and irMyositis and increased *PDL1* mRNA levels in irMyositis. *PDL1* and *PDL2* expression have been shown to be driven by *IFNγ*.^[@R31]^ Consistent with this report, *IFNγ* mRNA levels were significantly elevated in sIBM and IMNM samples compared to control, with significantly higher levels in sIBM than in muscle tissues of IMNM cases. *IFNγ* is a key regulatory molecule of cytotoxic T cells (CTLs),^[@R32],[@R33]^ and CTLs have been reported to invade skeletal muscle in sIBM and to a much lesser degree also in IMNM.^[@R1],[@R34]^ Thus far, there are no studies on the role of T cells in irMyositis in the literature. In this study, we now provided evidence that a subset of the invading T cells exhibit markers of severe T-cell exhaustion in sIBM, IMNM, and irMyositis.

Using immunohistochemistry and mRNA qPCR, we were able to detect high levels of gene expression for *PD1* and several other inhibitory coreceptors (KLRG1, LAG3, TIM3, EOMES, TBET) associated with a severely exhausted phenotype^[@R23]^ in sIBM skeletal muscle samples. In qPCR analysis of IMNM skeletal muscle biopsies, *TIM3* mRNA levels were significantly increased. TIM3 is an important marker for T-cell exhaustion^[@R8]^ and is a negative regulator of T-cell activation in infections^[@R35],[@R36]^ and cancer.^[@R37]^ In addition, TIM-3 is a key modulator of T-cell activation and disease severity in autoimmune disease.^[@R26],[@R38]^ T-cell exhaustion predicts favorable outcome in several immune-mediated diseases.^[@R25]^ Correlating clinical outcome with expression levels of exhaustion markers was beyond the scope of this study, but might explain in parts the heterogeneous findings in this group. Hence, we demonstrate that T cells in skeletal muscles of patients with IMNM can show an "exhausted" phenotype, which might be the consequence of prolonged exposure of these cells to high levels of autoantigen. Levels of autoantigens in sera of IMNM patients are actually directly associated with disease activity and creatine kinase levels.^[@R3]^ This also indirectly fosters the hypothesis that anti-SRP and anti-HMGCR autoantibodies play decisive roles in IMNM.^[@R1]^ We did not find any significant difference in expression levels between anti-HMGCR^+^, and anti-SRP^+^ IMNM, and interindividual variance was high among IMNM samples.

Expression of PD1 and other markers for T-cell exhaustion and T-cell senescence in tumor infiltrating T cells, as well as the expression of PD1 ligands on tumor cells have been well studied in several cancers. Inducing and maintaining T-cell inhibition through activation of inhibitory molecules on tumor-specific T cells have been implicated as one of the driving mechanisms for tumor immune escape.^[@R23]^ Blocking these inhibitory signals leads to robust beneficial anticancer immune responses.^[@R39],[@R40]^ In this study, we provide the first evidence that T cells in irMyositis acquire an exhausted phenotype with high expression of PD-1, LAG-3, and TIM-3, reflecting a similar pattern found on tumor infiltrating T cells.^[@R23]^ Interestingly, in 2 severe cases of irMyositis with associated immune myocarditis, we observed no signs of T-cell exhaustion in our samples but distinct markers of T-cell senescence. These samples exhibited high surface expression levels of CD57 and low expression of *CD28* and *PD1.*^[@R41]^ There was no association with the delay from symptom onset to biopsy or specific immunosuppressive treatment before biopsy. Further studies with larger sample sizes are needed to confirm the association of symptom severity and T-cell senescence. Differences in the distribution of weakness and frequency of a concomitant autoimmune myocarditis between cases showing predominantly T-cell exhaustion or T-cell senescence would be of particular interest. Consistent with previous reports addressing CD57 expression on invading T cells in sIBM,^[@R17]^ we also found CD57 expression in samples of sIBM. Furthermore, expression levels of KLRG1 and CD244 were significantly increased in sIBM samples as markers of exhaustion as well as T cell differentiation.^[@R12],[@R23]^ However, *IL7R*, a receptor typically downregulated in exhausted T cells and involved in a sustained effective T-cell response,^[@R8]^ was also significantly upregulated in our sIBM samples. These findings suggest a heterogenous composition of senescent, exhausted, as well as differentiated cytotoxic invading T cells in sIBM. Analyzing T-cell subsets in the peripheral blood and muscle infiltrates of sIBM patients has previously revealed an oligoclonal expansion of CD8^+^ T cells and a deficiency of regulatory T cells,^[@R42]^ and the PDL1-PD1 axis has been shown to convert Th1 cells into T regs.^[@R43]^ Our finding of pronounced T-cell exhaustion and senescence in sIBM samples corroborates the notion of sIBM as a primarily inflammatory myopathy.

In this study, we report retrospective analyses of skeletal muscle biopsies with confirmed sIBM, IMNM, and irMyositis. We were therefore unable to analyze expression patterns on a single-cell level to further disentangle different invading T cell subsets, which might lead to a misinterpretation of the prevailing T-cell population. Nevertheless, in this study, we present clear evidence of T-cell exhaustion, and T-cell senescence to varying degrees in all 3 studied myositis entities: In IMNM samples, we found evidence of exhaustion, but no signs of senescence. Clearer signs of T-cell exhaustion were visible in irMyositis with a subset of patients showing markers of T-cell senescence, but not of exhaustion. In sIBM, we found high expression of markers for T-cell exhaustion and T-cell senescence. Differences in the duration of disease might interfere with the immune phenotype of the entities studied herein. Taken together, our findings implicate the involvement of muscle-specific T cells with specific phenotypes in the development of sIBM, IMNM, and irMyositis. Activation of coinhibitory receptors could therefore be a viable treatment target in sporadic immune-mediated myositis entities mandating further prospective studies correlating markers of T-cell exhaustion with clinical outcome.
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:   cytotoxic T cell
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:   3-hydroxy-3-methylglutaryl-coenzyme A reductase
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:   immune checkpoint inhibitors
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:   immune mediated necrotizing myopathy

IFNγ

:   gamma interferon

irMyositis

:   myositis induced by immune checkpoint inhibitors
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:   major histocompatibility complex
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:   programmed cell death protein 1

PD-L1/2

:   ligand of programmed cell death protein 1/2
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:   sporadic Inclusion body myositis
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:   signal recognition particle
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